Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCFinancial_Report.xls
10-Q - QUARTERLY REPORT - KERYX BIOPHARMACEUTICALS INCv318892_10q.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR17.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR15.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR18.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR19.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR21.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR23.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR22.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR13.htm
EX-31.1 - EXHIBIT 31.1 - KERYX BIOPHARMACEUTICALS INCv318892_ex31-1.htm
EX-32.1 - EXHIBIT 32.1 - KERYX BIOPHARMACEUTICALS INCv318892_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - KERYX BIOPHARMACEUTICALS INCv318892_ex31-2.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR9.htm
EX-32.2 - EXHIBIT 32.2 - KERYX BIOPHARMACEUTICALS INCv318892_ex32-2.htm
v2.4.0.6
Summary of Stock Option Activity (Detail) (Stock Options, USD $)
6 Months Ended 12 Months Ended
Jun. 30, 2012
Dec. 31, 2011
Stock Options
   
Number of shares    
Outstanding at beginning of period 3,517,000  
Granted 516,500  
Exercised     
Forfeited (236,208)  
Expired (20,000)  
Outstanding at end of period 3,777,292 3,517,000
Vested and expected to vest at June 30, 2012 3,738,001  
Exercisable at June 30, 2012 2,554,418  
Weighted-average exercise price    
Outstanding at beginning of period $ 6.40  
Granted $ 2.35  
Exercised     
Forfeited $ 8.32  
Expired $ 10.17  
Outstanding at end of period $ 5.70 $ 6.40
Vested and expected to vest at June 30, 2012 $ 5.73  
Exercisable at June 30, 2012 $ 6.68  
Weighted-average contractual term    
Outstanding at beginning of period 6 years 4 months 24 days 6 years 10 months 24 days
Granted 10 years  
Outstanding at end of period 6 years 4 months 24 days 6 years 10 months 24 days
Vested and expected to vest at June 30, 2012 6 years 4 months 24 days  
Exercisable at June 30, 2012 5 years 6 months  
Aggregate intrinsic value    
Outstanding at beginning of period $ 2,139,130  
Exercised     
Outstanding at end of period 1,412,908 2,139,130
Vested and expected to vest at June 30, 2012 1,405,622  
Exercisable at June 30, 2012 $ 1,195,408